Revision 4

Store at -20C

#8944

CEND1 (D6A6) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP, IF-F	H M R	Endogenous	22	Rabbit IgG	#Q8N111	51286

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:100
Immunofluorescence (Frozen)	1:400

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

CEND1 (D6A6) Rabbit mAb recognizes endogenous levels of total CEND1 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human CEND1 protein.

Background

The progression of progenitor cells towards neuronal differentiation is regulated by cell cycle control and the transition from proliferative to neurogenic cell divisions. Cell cycle exit and neuronal differentiation 1 (CEND1) is a neuronal protein widely expressed in the adult nervous system (1). It is implicated in the synchronization of cell cycle exit and differentiation of neuronal precursors in the developing nervous system, and its expression marks the exit of proliferative cells from the cell cycle (2,3). Levels of CEND1 expression in the subventricular zone of the adult nervous system are critical for cell cycle control and neuronal differentiation mechanisms during neonatal SVZ neurogenesis (4). It has recently been shown that neural progenitor cells (NPCs) that overexpress CEND1 display increased neuronal differentiation in a mouse model of brain injury, suggesting its potential use as a therapeutic intervention for neurodegenerative diseases and brain injury (5).

Background References

1. Patsavoudi, E. et al. (1995) *J Neurosci Res* 40, 506-18.
2. Politis, P.K. et al. (2007) *Proc Natl Acad Sci USA* 104, 17861-6.
3. Koutmani, Y. et al. (2004) *Eur J Neurosci* 20, 2509-23.
4. Katsimpardi, L. et al. (2008) *Stem Cells* 26, 1796-807.
5. Makri, G. et al. (2010) *Stem Cells* 28, 127-39.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation **IF-F:** Immunofluorescence (Frozen)

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat

Trademarks and Patents

Limited Uses

purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.